The investigational drug BMS-986365 may help patients with mCRPC previously treated with ARPIs overcome drug resistance, despite their genomic status. The investigational dual androgen receptor ...
“This finding implicates that targeting PCNA/AR interaction could be an innovative strategy for therapy against CRPC.” In this study, authors Shan Lu and Zhongyun Dong from the University of ...
A TTUHSC research team led by Srinivas Nandana, Ph.D., (center) and Manisha Tripathi, Ph.D., (left) recently completed a study focused on uncovering the molecular and signaling mechanisms that drive ...
A large team of researchers led by Wouter Karthaus, head of the Endocrine Therapy Resistance and Molecular Genetics Lab at ...
Transcriptomic Profiling of Primary Prostate Cancers and Nonlocalized Disease on Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography: A Multicenter Retrospective Study ...
A poorly characterized protein, historically thought to be a chaperone or enzyme, may actually be a key player in prostate cancer. In a systematic CRISPR screen, scientists from Arc Institute, UCSF, ...
Morning Overview on MSN
Scientists watch drug molecules hit cell receptors in real time
Drug discovery is shifting from static snapshots to moving pictures. Instead of inferring how medicines work from end results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback